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The role of Negative Pressure Wound Therapy in
the management of orocutaneous fistulas in cancer
patients – a case series
Iwona A. Niedzielska, Katarzyna M. Ściskała, Michał M. Bąk, Damian Niedzielski
CASE REPORT
Abstract—Background: Negative Pressure Wound Therapy
(NPWT) is used in the treatment of various wounds. The study
demonstrates a novel use of vessel patch as a sealant of mucosal
orifice fistulas.
Methods: The study included ten patients with orocutaneous
fistulas in the course of treatment of oral malignancies. Patients
were divided into treatment (NPWT) and control (conventional
dressings) group. In four cases, the vessel patch was applied.
We used the Hartmann Vivano system with 50 mmHg to 130
mmHg negative pressure values.
Results: The median age of patients was 61.5 years (range:
31 – 73 years). The median treatment time was 83 days (range:
14 – 272 days). The median total treatment cost was 5.300 EUR
(range: 2490 – 7821 EUR) in the NPWT group and 12.000 EUR
(range: 3.060 – 22.745 EUR) in the control group.
Conclusion: The use of NPWT is a cost-effective and reason-
able method for the management of orocutaneous fistulas and
other complications in maxillofacial surgery.
Keywords—NPWT, orocutaneous fistulas, cancer,
Introduction
THE frequency of cutaneous fistulas formation afterreconstruction surgery of head and neck varies between
2% to 66%.1 Frederick et al. reported this complication
in 3% of cases in their retrospective study carried out on
1,000 patients with the use of free vascularized tissue grafts.2
Sousa et al. noted that among patients who underwent a
total laryngectomy, the incidence of fistula formation was
15%, and it was the most common complication in this
group of patients. The mean time to fistula formation was 3.5
days, with a standard deviation of 13.7 days. Malnutrition,
positive surgical margins, the necessity of neck dissection, the
presence of tracheostomy, tumor stage, and prior radiotherapy
are considered to be contributing factors to fistula formation.
However, a mechanistic dependency between those factors
and fistula incidence has not been demonstrated.3
Moreover, surgical reconstruction promoting insufficient
vascular viability of the tissues, poor suturing technique
failing to provide watertight connection, and the contamina-
tion from the upper gastrointestinal tract contribute to fistula
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formation.4 Orocutaneous and pharyngocutaneous fistulas
cause serious inconvenience for patients. Applying dressings
or covering them is widely restricted, and they may impede
oral feeding.1
Furthermore, the occurrence of fistulas prolongs hospital-
ization time, raise therapy costs, and may postpone adjuvant
therapy.5 There is an agreement that cutaneous fistulas should
be initially treated conservatively with antibiotics, wound
cleansing with the application of conventional dressings,
and transition to enteral feeding.3, 5 A fraction of fistulas
responds to this type of treatment. Sousa et al. reported
successful closure by nonsurgical means in all cases.3 Nev-
ertheless, McNeal et al. reported that spontaneous closure
of pharyngocutaneous fistulas occurred after an average of
50 days (range: 10 – 120 days) among all the patients and
24 days (range: 14 – 60 days) in patients who did not
receive radiotherapy.6 Still, some fistulas do not respond to
conservative treatment and require surgical treatment,5, 7
Lately, the usefulness of Negative Pressure Wound Ther-
apy (NPWT) in the treatment of orocutaneous and pharyngo-
cutaneous fistulas was discussed by Andrews et al.8 in 2008,
Dhir et al.9 in 2009, Tay et al.10 in 2011 in a case report,
Tian et al.5 in 2013 in a study based on Tay report, Yang et
al.4 in 2013 and Kojima et al.7 in 2015. In this latest study,
Kojima et al. sutured the cutaneous side of fistulas to achieve
airtightness and applied negative pressure of –200 mmHg.7
On the other side, Yang et al. emphasized the necessity of
suturing the mucosal side of the fistula.4 Tay et al. and Tian
et al. achieved the seal on the mucosal side of the fistula
with cotton gauze immersed in the dental alginate impression
material.5, 10 In this paper, we present a novel method of
sealing the mucosal side of the fistula with the use of a non-
resorbable vessel patch. The application of the vessel patch
facilitates the watertight suturing on the mucosal side of the
fistula, thus stopping the salivary leak into the fistula.
This solution has the following advantages:
1) facilitates watertight suturing on the mucosal side of
fistula avoiding unnecessary tension,
2) allows watertight suturing in the situation of tissue
deficit when it is impossible to repair the defect by
primary closure
3) brings together and stabilizes wound margins, and
4) provides a watertight seal, thus stopping the saliva
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leakage independently of the NPWT usage on the
cutaneous side.
The last one simplifies the conventional wound care be-
cause dressings are loaded with less exudate. It is worth not-
ing that (5) once sutured, the vessel patch stays in place and
does not require replacement when the cutaneous dressings
are changed (these can be either conventional or NPWT).
We have not found any prior reports on such usage of ves-
sel patches in the literature. Vessel patches or vascular pros-
theses are commonly used in cardiac and vascular surgery in
the treatment of injuries, aneurysms, congenital defects, and
repairing defects of vessels and cardiac walls.11 They are
produced from biocompatible synthetic polymers or autol-
ogous, allogenic, or xenogenic pericardium.12 Polyethylene
terephthalate (PET), and Polytetrafluoroethylene (ePTFE)
have been used in cardiac surgery due to their mechanical
properties and satisfactory durability.11, 12 This paper aims to
evaluate the usefulness of NPWT and its combination with a
vessel patch application in the management of orocutaneous
fistulas in head and neck cancer patients.
Materials and methods
A. Patients
The study included patients with orocutaneous fistulas
treated in the dep of Cranio-Maxillo-Facial and Oral Surgery
of Silesian Medical University in Katowice between 2012 and
2014. Patients were divided into two groups: the treatment
group (NPWT) and the control group (conventional dress-
ings).
The inclusion criteria were:
1) the presence of orocutaneous fistula verified with dye
test and
2) lack of possibility or indications for surgical manage-
ment of the fistulas. The study included ten patients.
B. Wound management
Physicians performed all the wound care procedures.
NPWT dressings were changed every two to three days,
and the conventional dressings were changed every day.
The diagnosis of orocutaneous fistula was based on clinical
examination and confirmed by the dye test with iodopovi-
done. The mucosal orifice of the fistula was flushed with
water iodopovidone solution Braunol (B.Braun, Melsun-
gen, Germany). In the presence of an orocutaneous fistula,
iodopovidone solution appeared on the skin surface. In all
cases, mucosal orifices were identified. In order to seal
the mucosal opening of the fistula and to stop the saliva
leakage in 4 cases (1, 2, 6, 7) the vessel patch was tightly
sutured to the margins of the mucosal orifice with the use
of polypropylene monofilament sutures (Dafilon, B.Braun,
Melsungen, Germany). We present an application of vessel
patch as a mucosal side sealant of orocutaneous fistulas.
The use of the vessel patch allowed us to maintain the
pressure necessary to facilitate an effective NPWT in the
wound bed. Moreover, in both treatment and control groups,
the application of the vessel patch ceased the saliva seepage.
Shape stability of the vessel patch provides stabilization
for fistula margins and increases the tendency to intraoral
component closure by keeping margins closer to each other.
In the control group the cutaneous side of the fistula was
managed conventionally with silver dressings Aquacel Ag
(ConvaTec, Bridgewater Township, NY, USA), Atraumann
Ag (Paul Hartmann, Heidenheim an der Brenz, Germany),
alginate dressing Sorbalgon (Paul Hartmann, Heidenheim
an der Brenz, Germany) and iodopovidone or 10% NaCl
compresses. In the treatment group, the NPWT dressing was
applied on the cutaneous side of the fistula.
Before the introduction of the NPWT, necrotic tissues were
removed from the wounds by surgical necrotomy. We used
special wound dressings — Tender Wet (Paul Hartmann,
Heidenheim an der Brenz, Germany) or lavaseptics with the
use of an aqueous solution of octenidine and phenoxyethanol
— Octenisept (Schülke & Mayr, Norderstedt, Germany). The
NPWT system used in this study was Vivano (Paul Hartmann,
Heidenheim an der Brenz, Germany) consisting of vacuum
producing device VivanoTec, exudate canister VivanoTec,
VivanoTec Port with multi-lumen drain and VivanoMed
dressing kit. The dressing used in this study was the black
microporous polyester polyurethane VivanoMed Foam. The
sterile foam dressing was adjusted to wound shape, and then
it was sealed with semipermeable Hydrofilm foil. Due to the
complex anatomy of the head and neck and the presence of
foramina, which reduced the surface available for sticking the
foil, it was vital to shave the facial hair and degrease the skin
meticulously. The latter was achieved by using Kodan Tinktur
forte (Schülke & Mayr, Norderstedt, Germany). Hydrofilm
foil prevents the infection by maintaining the moisture and
simultaneously stops the growth of anaerobic bacteria due
to its permeability. In order to avoid skin maceration, the
skin at the margins was protected with Atraumann Ag (Paul
Hartmann, Heidenheim an der Brenz, Germany) or Gras-
solind (Paul Hartmann, Heidenheim an der Brenz, Germany)
dressings. Patients were administered empirical or targeted
antibiotics. No drugs reducing salivary output were used. The
research was approved by the Medical University of Silesia
Local Ethics Board.
Results
The study included ten patients who developed ten oro-
cutaneous fistulas. The group consisted of seven men and
three women with a median age of 61.5 years (range, 31 –
73 years). Three patients had no comorbidities (3, 6, 10).
The rest suffered from cardiovascular diseases. Moreover,
one patient (5) was diagnosed with asthma-COPD overlap
syndrome and chronic rhinosinusitis; the other one (8) was
also treated for non-insulin-dependent diabetes mellitus. One
patient also suffered from Osler-Weber-Rendu disease com-
plicated with secondary anemia.
Regarding the type of surgery that led to complications, it
can be said that orocutaneous fistulas formed in patients who
underwent: (1) segmental resection of mandible with free
nonvascularized hip bone graft reconstruction and a locking
plate together with selective neck dissection in four cases (1,
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Table I
Patient demographics and tumor characteristics
# Age/
sex
Smoker Comorbidities Family history Previous
HNSCC
Prior RT Pathology TNM Type of surgery






No No SCC of the floor
of mouth
T4N2cM0 Segmental resection of
mandible. Reconstruction
with free nonvascularized
hip bone graft and
reconstruction locking
plate. SND.













N/A Sequestrectomy and fis-
tula closure.
3 67/M Y No No No No SCC of the floor
of mouth













5 64/M Y Prostate can-
cer RT treat-
ment
No No No SCC of the floor
of mouth
T3N1M0 Segmental resection of the
mandible. Reconstruction
with reconstruction lock-
ing plate and Bakamijan
flap. SND.
6 31/M Y No No No No Ameloblastoma
of the mandible
body in the area
from 37 to 32
N/A Segmental resection of
mandible. Reconstruction
with free nonvascularized
hip bone graft and
reconstruction locking
plate. SND.
7 55/M Former HT Mother: CNS tu-
mor
No No SCC of the floor
of mouth
T4aN2bM0 Segmental resection of
mandible. Reconstruction
with free nonvascularized
hip bone graft and
reconstruction locking
plate. SND.






No No SCC of the floor
of mouth












No No SCC of the floor
of mouth
T2N2bM0 Resection of tumor of oral
cavity. SND.
10 59/K Y No No No Yes (no
medical
records)
SCC of the floor
of mouth
T3N2aM0 Segmental resection of
mandible. Reconstruction
with free nonvascularized
hip bone graft and
reconstruction locking
plate. SND.
ACOS — asthma-COPD overlap syndrome, CABG — coronary artery bypass graft, HHT — Hereditary hemorrhagic telangiectasia, Osler-Weber-
Rendu disease, HT — hypertension, IHD – ischaemic heart disease, NIDDM — non-insulin-dependent diabetes mellitus, PAD — peripheral
artery disease, SCC — squamous-cell carcinoma, SND — selective neck dissection, *Interrupted because of reconstruction plate exposure

























No 5 31 Continuous mode: –100, –85
mmHg







No 3 36 Continuous mode: –50, –75, –
85, –90 mmHg






No 7 31 Continuous mode: –125
mmHg














38 Continuous mode: –85, –120,
–130 mmHg








Neck incision Surgical fistula
closure




Neck incision Removal of free
bone graft. Surgi-
cal fistula closure





















4 0 No NPWT N 83 T: 14.987e
D: 21e
T — total treatment cost, D — dressings cost, RT — radiotherapy group and 463 euro (range, 124 – 1282 EUR) in NPWT group. All above-mentioned
values where calculated with the exchange rate of 4,20 PLN for 1 EUR, patient stopped showing up to our outpatient clinic, Time from surgery to
fistula formation (days)
6, 7, 10); (2) segmental resection of mandible with locking
plate reconstruction, together with selective neck dissection
in cases (3, 4, 8); (3) resection of squamous cell carcinoma
of the floor of the mouth in one case (9); (4) surgical
treatment of osteoradionecrosis of mandible caused in the
course of adjuvant radiation therapy for oral carcinomas in
2 cases (2, 5); (5) segmental resection of mandible with free
nonvascularized hip bone graft reconstruction using a locking
plate in the course of ameloblastoma treatment in one case
(6). Median time from surgery to fistula diagnosis was six
days (range, 3 – 15 days). In one case (4), the fistula formed
in the course of radiation therapy and the cutaneous orifice
revealed as a suppurative fistula in the submental region. In
all the other cases, the cutaneous orifice of fistulas formed
in surgical incisions.
Patient demographics and tumor characteristics are pre-
sented in (Tab. I). Nine of 10 patients were hospitalized
due to squamous cell carcinoma or complications of its
treatment, whereas one patient (6) was treated because of
ameloblastoma of the mandible. Seven patients (1, 3, 4, 6, 7,
8,10) underwent segmental resection of the mandible, two
(2, 5) underwent sequestrectomy, and one (9) underwent
resection of tumor of the oral cavity. Selective neck dissection
was performed on seven patients (1, 3, 4, 7, 8, 9, 10). In
four cases (1, 6, 7, 10), reconstruction of resected mandible
was performed with free nonvascularized hip bone graft and
reconstruction locking plate, while in three cases (3, 4, 8),
the reconstruction plate was used standalone. One patient
underwent a tracheotomy. Treatment time was defined as the
time between fistula diagnosis and complete wound healing
recorded in patients’ medical history. For one patient (2),
recorded treatment time represents the time from fistula
diagnosis to the time he stopped showing up to our outpatient
clinic has not, and we excluded it from the statistical analysis.
The median treatment time was 83 days (range, 14 – 272
days) for all patients, whereas, in the NPWT group, it was
94.5 days (range, 31 – 272 days). The median time in the
control group was 83 days (range, 14 – 180 days). The
specific data on wound therapy characteristics are shown in
(Tab. II). In two patients in the NPWT group, it was necessary
to apply the vessel patch in order to obtain a vacuum
seal. Once sutured in place, vessel patch facilitated vacuum
generation in wound bed regardless of NPWT dressings
changes. Besides, the vessel patch was applied in two patients
from the control group, which protected the lumen of fistula
from salivary infection.
In all patients from the treatment group, the NPWT system
Vivano (Paul Hartmann, Heidenheim an der Brenz, Germany)
was used. The continuous mode of therapy was used, and the
negative pressure values ranged from –50 mmHg to –130
mmHg. In one patient (5), additionally, the dynamic mode
of therapy was employed with the cycles of 5 minutes at –80
mmHg and subsequently 5 minutes at –120 mmHg. In one
case (2), there was a need to downgrade the negative pressure
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value because of the painful burning sensation reported by
the patient. In two patients from the control group (6, 7), in
whom the NPWT was not employed, and in one patient (4)
from the NPWT group, it was necessary to perform additional
surgical procedures in order to close the fistulas finally.
Furthermore, for all the patients, we performed the analysis
of total treatment costs regarding the cost of hospital stay,
operating theater, and dressing materials used. This data is
presented in (Tab. II). The median of the total treatment
cost for all patients was 7498.5 EUR (range, 3.060 – 22.745
EUR); in the control group, it was 12.000 EUR (range, 3.060
– 22.745 EUR) whereas in NPWT group it was 5.300 EUR
(range, 2490 – 7821 EUR). Median of dressing materials
cost was 90.5 EUR (range, 7 – 1282 EUR) for all patients,
13 EUR (range, 7 – 57 EUR) in the control group, and 463
EUR (range, 124 – 1282 EUR) in NPWT group. All the
values mentioned above were calculated with the exchange
rate of 4.20 PLN for 1 EUR.
Discussion
Nowadays, Negative Pressure Wound Therapy is com-
monly applied in orthopedic traumatology, soft tissue in-
juries, management of skin grafts, treatment of pressure
ulcers, diabetic foot, venous ulcers, and burns. NPWT also
aids in fighting against Surgical Site Infections and treatment
of Impaired Wound Healing.13 The literature data on NPWT
application in the treatment of cutaneous fistulas in the head
and neck region consists of papers by Andrews et al.,8 Dhir
et al.,9 Tay et al.,10 Tian et al.,5 Yang et al.,4 and Kojima et
al.7 Yang et al. emphasize that the application of NPWT may
constitute a useful indicator of mucosal side water tightness,
moreover by obliteration of dead spaces, it prevents the
damage of large vessels and reduces the total treatment cost.
In general, NPWT is depicted by Yang et al. as a convenient
treatment modality for orocutaneous fistulas, which facilitates
infection control and fistula obliteration.
Tian et al. strongly recommend the use of NPWT in the
treatment of orocutaneous fistulas, as none of the patients in
their study experienced side effects of NPWT. Moreover, the
authors indicate that the development of NPWT complica-
tions may result from either inappropriate patient selection
or an incorrect NPWT application manner.5 Our observation
is similar to the authors mentioned above – the median of
total treatment cost in the NPWT group is lesser than in the
control group, and the complication of NPWT usage in the
form of pain and burning sensation was eliminated by more
accurate surrounding skin protection. The study by Kojima et
al. stands slightly in opposition to Yang et al. and Tian et al.
studies, and our observation. They reported the lack of seal of
NPWT dressings even when the negative pressure value was
lowered to –200 mmHg. As a reason, the authors indicate: (1)
complex outline of the wounds; (2) presence of facial hair;
(3) the proximity to tracheostomy; (4) the communication
of fistula with oral cavity and/or pharynx; (5) reduced tissue
elasticity due to prior radiation therapy. Moreover, in this
study, the use of NPWT raised the total therapy cost because
of elongating the hospitalization time.7
Our observation indicates that achieving the water tight-
ness on the mucosal side of the fistula and thorough shaving
of facial hair and skin degreasing provided sufficient seal for
the dressings. Indeed after three days, the facial hair in males
started to impair the dressing seal. Nevertheless, it seems that
before the mentioned time, it is irrelevant.
The action of NPWT is based on (1) draining the patho-
logical exudates from the wound bed,14–27 (2) reducing the
edema,15–18, 20, 21, 25–28 and maintaining the humid environ-
ment.16, 17, 25, 29 The positive effect of NPWT on leuko-
cytes and fibroblasts migration22, 27, 30 and accumulation of
growth factors27, 30 has been demonstrated. Lower concen-
trations of metalloproteinases (MMPs)31 and raised levels
of interleukin 8 (IL-8) and vascular endothelial growth fac-
tor (VEGF)18 have been observed. Analysis performed by
Glass et al. stated that NPWT significantly reduces tumor
necrosis factor (TNF) concentration in acute and chronic
wounds and interleukin 1 beta (IL-1β) in acute wounds
while having no influence on interleukin 6 (IL-6) levels.
NPWT raises interleukin 10 (IL-10) systemic levels and
interleukin 8 (IL-8) tissue concentrations. It raises VEGF
and basic fibroblast growth factor (bFGF, FGF2) excre-
tion and reduces the expression of metalloproteinases 1,
2, 9, and 13.32 This treatment modality enhances wound
blood supply15–17, 17–20, 23, 24, 27, 33 by angiogenesis stimula-
tion.16, 18–20, 25, 33, 34 Worth noting is remarkably significant
influence of this therapy on proliferation of cells,18, 19, 25
granulation tissue formation14–20, 24, 25, 29, 33, 34 and epithe-
lialization.18, 20 Moreover NPWT leads to wound area re-
duction9 by contraction of wound margins.14, 16, 18, 19, 25 The
optimal negative pressure value is –125 mmHg.14–19, 22, 25, 30
Regarding the expected effect of therapy, this value can be
changed.14 According to literature data immediately upon
surgical wound debridement, it is recommended to set nega-
tive pressure values between –150 mmHg and –200 mmHg,
however, for the granulation tissue formation stimulation, it
is advisable to lower the values to –110 mm Hg to –130
mmHg.21
There are reports on the use of negative pressure values not
exceeding –80 mmHg in order to minimize the possible tissue
injury.22 Furthermore, the cases were described in which the
negative pressure values were set to –50 mmHg in the therapy
of ischemic wounds (Critical Limb Ischemia) providing satis-
factory results without wound margins necrosis23 According
to Malmsjö et al., there are no significant differences in
wound healing between negative pressure values of –50
mmHg, –75 mmHg, and –125 mmHg. Furthermore, the blood
flow at –80 mmHg is similar to that at –125 mmHg. In
conclusion, the authors suggest the use of higher pressure
values in painful wounds with poor blood supply13 Because
of the anatomic factors NPWT in the region of head and neck
is not straightforward in use; however, it is highly efficient
in the treatment of impaired wound healing. Undoubtedly
further investigation on the mechanism of action of NPWT
is warranted. Likewise, there is little evidence on the use of
NPWT in orocutaneous fistulas treatment, and further trials
should be conducted. In this paper, we described a novel
method of sealing a mucous-end fistula orifice preventing
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the salivary penetration. The dressings in the NPWT group
were changed every 2 to 3 days, which turned out to be both
cost-effective and convenient for patients.
Conclusions
The application of Negative Pressure Wound Therapy is a
reasonable treatment modality for complications in maxillo-
facial surgery, including orocutaneous fistulas.
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